Denali Therapeutics Inc (NASDAQ:DNLI) announced new interim results from the ongoing open-label, single-arm Phase 1/2 study of DNL310 in children with…
ViiV Healthcare, majority-owned by GSK Plc (NYSE:GSK), Pfizer Inc (NYSE:PFE), and Shionogi Limited, announced 12-month findings from the SOLAR Phase 3b study of the long-acting injectable…
The plan will halt research and development efforts on INP105 (olanzapine) to address acute agitation and aggression in autism spectrum disorder.
Aligned with this, the Company also announced that Stephen
Study findings showed that CAB+RPV LA dosed every two months achieved the primary endpoint of non-inferior virologic efficacy versus daily oral BIC/FTC/TAF, while 90% of participants who switched to CAB+RPV